Experimental and Clinical Evidence of Endothelial Dysfunction in Inflammatory Bowel Disease

2020 ◽  
Vol 26 (30) ◽  
pp. 3733-3747 ◽  
Author(s):  
Mariana Ferreira-Duarte ◽  
Joana Beatriz Sousa ◽  
Carmen Diniz ◽  
Teresa Sousa ◽  
Margarida Duarte-Araújo ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Endothelial Dysfunction ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
High Cardiovascular Risk ◽  
Considerable Evidence ◽  
Chronic Inflammatory Condition ◽  
Inflammatory Bowel ◽  
Repurposed Drugs ◽  
Main Effects

The endothelium has a crucial role in proper hemodynamics. Inflammatory bowel disease (IBD) is mainly a chronic inflammatory condition of the gastrointestinal tract. However, considerable evidence points to high cardiovascular risk in patients with IBD. This review positions the basic mechanisms of endothelial dysfunction in the IBD setting (both clinical and experimental). Furthermore, we review the main effects of drugs used to treat IBD in endothelial (dys)function. Moreover, we leave challenging points for enlarging the therapeutic arsenal for IBD with new or repurposed drugs that target endothelial dysfunction besides inflammation.

Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence

2017 ◽  
Vol 10 (4) ◽  
pp. 391-400 ◽  
Author(s):  
Sean McConachie ◽  
Sheila M. Wilhelm ◽  
Pramodini B. Kale-Pradhan
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
Inflammatory Bowel

Clinical Evidence for Mobilization of Very Small Embryonic/Epiblast Like Stem Cells (VSEL-SCs) in Patients With Inflammatory Bowel Disease

2011 ◽  
Vol 140 (5) ◽  
pp. S-656
Author(s):  
Wojciech M. Marlicz ◽  
Wojciech Blogowski ◽  
Edyta Paczkowska ◽  
Magda Kucia ◽  
Malgorzata Lawniczak ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Stem Cells ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
Inflammatory Bowel

Profiling of histone 3 lysine 27 acetylation reveals its role in a chronic DSS-induced colitis mouse model

2019 ◽  
Vol 15 (4) ◽  
pp. 296-307
Author(s):  
Meng Chen ◽  
Qinglan Li ◽  
Nan Cao ◽  
Yanan Deng ◽  
Lianyun Li ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Gastrointestinal Tract ◽  
Mouse Model ◽  
Bowel Disease ◽  
Inflammatory Condition ◽  
Histone 3 ◽  
Chronic Inflammatory Condition ◽  
Inflammatory Bowel

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract.

scholarly journals The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease

2020 ◽  
Vol 8 (11) ◽  
pp. 1715
Author(s):  
Spase Stojanov ◽  
Aleš Berlec ◽  
Borut Štrukelj
Keyword(s):  
Inflammatory Bowel Disease ◽  
Weight Loss ◽  
Gastrointestinal Tract ◽  
Bowel Disease ◽  
Important Influence ◽  
Considerable Evidence ◽  
Bacterial Phyla ◽  
Genus Lactobacillus ◽  
Inflammatory Bowel ◽  
Treatment Of Obesity

The two most important bacterial phyla in the gastrointestinal tract, Firmicutes and Bacteroidetes, have gained much attention in recent years. The Firmicutes/Bacteroidetes (F/B) ratio is widely accepted to have an important influence in maintaining normal intestinal homeostasis. Increased or decreased F/B ratio is regarded as dysbiosis, whereby the former is usually observed with obesity, and the latter with inflammatory bowel disease (IBD). Probiotics as live microorganisms can confer health benefits to the host when administered in adequate amounts. There is considerable evidence of their nutritional and immunosuppressive properties including reports that elucidate the association of probiotics with the F/B ratio, obesity, and IBD. Orally administered probiotics can contribute to the restoration of dysbiotic microbiota and to the prevention of obesity or IBD. However, as the effects of different probiotics on the F/B ratio differ, selecting the appropriate species or mixture is crucial. The most commonly tested probiotics for modifying the F/B ratio and treating obesity and IBD are from the genus Lactobacillus. In this paper, we review the effects of probiotics on the F/B ratio that lead to weight loss or immunosuppression.

scholarly journals Quality of Life in Cohabitants of Patients Suffering Inflammatory Bowel Disease: A Cross-Sectional Study

2021 ◽  
Vol 19 (1) ◽  
pp. 115
Author(s):  
Manuel López-Vico ◽  
Antonio D. Sánchez-Capilla ◽  
Eduardo Redondo-Cerezo
Keyword(s):  
Quality Of Life ◽  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Chronic Inflammatory Condition ◽  
Inflammatory Bowel

(1) Background: Inflammatory bowel disease (IBD) is a chronic inflammatory condition with a significant impact on patients’ general health perception. No studies have considered consequences of IBD on cohabitants. (2) Aims: The aims of this study were to address the influence of IBD on cohabitants’ quality of life (QoL) and the factors potentially conditioning this impact. (3) Methods: We conducted a cross-sectional study in which IBD patients and their cohabitants were invited to participate. Validated questionnaires were used to measure QoL in patients and cohabitants. Main clinical and sociodemographic variables were collected. (4) Results: A total of 56 patients and 82 cohabitants with significant QoL impairment were included. A direct association was found between Inflammatory Bowel Disease Questionnaire (IBDQ32) score in patients and the Household Members Quality of Life—Inflammatory Bowel Disease (HHMQoL-IBD). IBDQ32 was related to the number of flares in the last 12 months, number of hospital admissions and Mayo Score. (5) Conclusions: HHMQoL-IBD score was related to patients IBDQ32 score and the presence of extraintestinal disease. We identified CRP, a marker of disease activity, as a factor related to cohabitants’ quality of life, pointing to a direct relationship of patients’ disease activity and their cohabitants’ quality of life.

Targeting Leukocyte Trafficking in Inflammatory Bowel Disease: What Is the Clinical Evidence?

2015 ◽  
Vol 33 (Suppl. 1) ◽  
pp. 95-104
Author(s):  
Reena Khanna ◽  
Mahmoud H. Mosli ◽  
Brian G. Feagan
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
Cellular Migration ◽  
Leukocyte Trafficking ◽  
Intestinal Tissue ◽  
Efficacy Data ◽  
Inflammatory Bowel ◽  
Inflammatory Drugs ◽  
Novel Targets

Since the cause of inflammatory bowel disease (IBD) is unknown, therapy has traditionally been based on the empiric use of anti-inflammatory drugs. However, the recent identification of specific mechanisms that regulate cellular migration into inflamed intestinal tissue has provided novel targets for drug development. In this article, we discuss these mechanisms and review emerging safety and efficacy data regarding use of selective inhibitors of leukocyte trafficking for the treatment of IBD.

scholarly journals Inflammatory bowel disease: Looking beyond the tract

2019 ◽  
Vol 33 ◽  
pp. 205873841986656 ◽  
Author(s):  
Sana Chams ◽  
Reina Badran ◽  
Skye El Sayegh ◽  
Nour Chams ◽  
Ali Shams ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Current Knowledge ◽  
Review Article ◽  
Organ System ◽  
Cancer Development ◽  
Extraintestinal Manifestations ◽  
Screening And Surveillance ◽  
Chronic Inflammatory Condition ◽  
Inflammatory Bowel

Inflammatory bowel disease is a chronic inflammatory condition that encompasses Crohn’s disease and ulcerative colitis. Inflammatory bowel disease is not exclusive to the gastrointestinal system, as it has been identified to be associated with extraintestinal manifestations that encompass every other organ system in the human body. This review article will comprehensively review the current knowledge on extraintestinal manifestations of inflammatory bowel disease. In addition, it will discuss the recommendations for screening and surveillance for extraintestinal manifestations in these patients since early appropriate diagnosis is imperative in preventing morbidity and cancer development.

Sign in / Sign up

Export Citation Format

Share Document